SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-079246
Filing Date
2023-07-10
Accepted
2023-07-07 21:49:57
Documents
14
Period of Report
2023-07-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2320867d1_8k.htm   iXBRL 8-K 40283
2 EXHIBIT 10.1 tm2320867d1_ex10-1.htm EX-10.1 120168
3 EXHIBIT 10.2 tm2320867d1_ex10-2.htm EX-10.2 84461
  Complete submission text file 0001104659-23-079246.txt   461790

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA srne-20230705.xsd EX-101.SCH 3319
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE srne-20230705_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srne-20230705_pre.xml EX-101.PRE 22383
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2320867d1_8k_htm.xml XML 3117
Mailing Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121
Business Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121 858-203-4100
Sorrento Therapeutics, Inc. (Filer) CIK: 0000850261 (see all company filings)

IRS No.: 330344842 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36150 | Film No.: 231078106
SIC: 2836 Biological Products, (No Diagnostic Substances)